---
title: "Clearfield (CLFD) Receives a Buy from Roth MKM"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285549243.md"
description: "Roth MKM analyst Scott Searle has maintained a Buy rating on Clearfield (CLFD) with a price target of $44.00. Searle, a 5-star analyst, has an average return of 18.0% and a 51.08% success rate. Additionally, Needham also reiterated a Buy rating on Clearfield with a price target of $45.00."
datetime: "2026-05-07T12:14:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285549243.md)
  - [en](https://longbridge.com/en/news/285549243.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285549243.md)
---

# Clearfield (CLFD) Receives a Buy from Roth MKM

Roth MKM analyst Scott Searle maintained a Buy rating on Clearfield today and set a price target of $44.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Searle is a 5-star analyst with an average return of 18.0% and a 51.08% success rate. Searle covers the Technology sector, focusing on stocks such as Adeia, Aviat Networks, and Sequans Communications S A.

In a report released today, Needham also reiterated a Buy rating on the stock with a $45.00 price target.

### Related Stocks

- [CLFD.US](https://longbridge.com/en/quote/CLFD.US.md)
- [ADEA.US](https://longbridge.com/en/quote/ADEA.US.md)
- [AVNW.US](https://longbridge.com/en/quote/AVNW.US.md)
- [SQNS.US](https://longbridge.com/en/quote/SQNS.US.md)

## Related News & Research

- [Clearfield Joins VoltServer's Solution Partner Program to Advance Digital Electricity® Adoption | CLFD Stock News](https://longbridge.com/en/news/286935726.md)
- [Clearfield Sees Fiber Demand Stabilizing as Bookings Rise, Data Center Prospects Build](https://longbridge.com/en/news/286124187.md)
- [Why This Analyst Thinks Texas Instruments Stock Is on the Path to $1 Trillion](https://longbridge.com/en/news/286957345.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)
- [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)